Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Tolerance and Pharmacokinetics of AL2846 in Patients With Advanced Cancer

NCT02779699 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT02779699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02779699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Tolerance and Pharmacokinetics of AL2846 in Patients With Advanced Cancer
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
May 31, 2016
Completion date
October 31, 2020
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer